ArticleFood science and biotechnology2025
Therapeutic potential of phytochemical luteolin in restoring skin barrier by inhibiting antimicrobial peptides associated with TRAF6/TAK1/IKK/IκB in psoriasis-like HaCaT models.
Article in Food science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Polyphenols as Multi-Target Regulators of Oxidative Stress, Mitochondrial Function, and Cell Survival Signaling in Skin Diseases.International journal of molecular sciences · 2026Review
- The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.Frontiers in immunology · 2026Review
- Protective Effect of Peony (Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune skin diseases, such as psoriasis are primarily characterized by excessive inflammation and skin barrier damage. The disrupted skin barrier is directly related to skin dryness. Luteolin, a flavonoid compound, has various biological activities such as antioxidant, anticancer, anti-aging, and anti-inflammatory. However, little has been known about the anti-psoriatic therapeutic function of luteolin. This study focused on the recovery of the skin barrier by luteolin through the regulation of antimicrobial peptides (AMPs) as well as anti-inflammatory activity, using TNF-α/IL-17A/IFN-γ-stimulated HaCaT cells. First, luteolin significantly inhibited the mRNA expression of antimicrobial peptides LL-37, human β-defensin-2 (hBD-2), S100A7, and S100A8 by regulating IκB/NF-κB signaling pathway through TRAF6/IκB. Moreover, luteolin increased the expression of filaggrin, loricrin and involucrin, which are essential of cornified envelope (CE) formation in epidermis. These results suggest anti-inflammatory luteolin has the function of restoring the disrupted skin barrier by regulating antimicrobial peptides and cornified envelope proteins. Supplementary Information: The online version contains supplementary material available at 10.1007/s10068-025-01894-z.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.